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Abstract
Background: In clinical practice, sleep disturbance is often regarded as an epiphenomenon of the primary mental
disorder. The aim of this study was to test if sleep disturbance, independently of primary mental disorders, is
associated with current clinical state and benefit from treatment in a sample representative of public mental health
care clinics.
Method: 2246 patients receiving treatment for mental disorders in eight public mental health care centers in
Norway were evaluated in a cross-sectional study using patient and clinician reported measures. Patients reported
quality of life, symptom severity, and benefit from treatment. Clinicians reported disorder severity, level of
functioning, symptom severity and benefit from treatment. The hypothesis was tested using multiple hierarchical
regression analyses.
Results: Sleep disturbance was, adjusted for age, gender, time in treatment, type of care, and the presence of any
primary mental disorder, associated with lower quality of life, higher symptom severity, higher disorder severity,
lower levels of functioning, and less benefit from treatment.
Conclusion: Sleep disturbance ought to be considered a stand-alone therapeutic entity rather than an
epiphenomenon of existing diagnoses for patients receiving treatment in mental health care.
Background
Sleep disturbance affects 50% to 80% of all patients with
mental disorders and it is currently a symptom of 19
axis I disorders [1-3]. At the same time, it is considered
to be a disorder in itself if the sleep disturbance impairs
daily functioning [4,5]. With this diagnostic multitude,
there is a possibility that clinicians regard the sleep dis-
turbance as an epiphenomenon that will be dissolved
once the primary mental disorder is treated and not as a
valid stand-alone clinical entity [1]. This distinction can
have consequences for choice of treatment for these
patients [1] and sleep disturbance is poorly recognized
when patients have a mental disorder [6,7].
The relationship between sleep and mental disorders
is complex and not fully understood. Sleep disturbance
may precede depression [8-10], and 40% to 70% of
patients who are successfully treated for depression
experience sleep disturbance as a residual symptom
[11-13]. On the other hand, the remission rate following
anti-depressive treatment can be doubled if adjunct
treatment for sleep disturbance is provided [14], and de-
pression can be treated using cognitive behavior therapy
for insomnia alone [15]. These findings challenge the
assumption that the sleep disturbance is secondary to
a primary disorder. It may be better conceptualized as
a comorbid condition, at least in depression. In a state-
of-the-science statement the National Institutes of Health
(NIH) recommended that when insomnia occurs concur-
rent with other disorders it should be considered comor-
bid rather than secondary [16]. In the online draft for the
DSM-5, this recommendation is taken into consideration
and a paradigm shift is proposed as to how sleep disturb-
ance should be conceptualized in patients with mental
disorders [17]. It is suggested that insomnia should always
be coded if the criteria are fulfilled, regardless of meeting
criteria for other disorders.
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Most research so far on the association between sleep
disturbance and mental disorders have been conducted
in selected patient groups, mostly depressed patients,
that may not fully resemble the heterogeneous group of
patients found in public health care systems. The clinical
usefulness of the NIH recommendation to regard insom-
nia as a comorbid disorder, rather than an epiphenom-
enon to a primary mental disorder, would be further
supported if it was demonstrated that sleep disturbance
is associated with distress and disability independently of
the patients’ primary diagnosis also in settings represen-
tative of mental health care. Studies investigating such
associations may be particularly relevant now with the
advent of the DSM-5 proposal. However, no studies have
been conducted to test if sleep disturbance is associated
with current clinical state and benefit from treatment for
patients representative of clinical settings. The aim of
the current study was thus to test the hypothesis that
sleep disturbance, independently of the patients’ primary
mental disorder, is associated with variations in quality
of life, disorder and symptom severity, level of function-
ing, and benefit from treatment in a large, heterogenous,
clinical sample.
Method
Procedure
The data in this cross-sectional study were collected
from eight general mental health care centers during
eight weeks in 2002 and four weeks in 2005. The data
collections were commissioned by the Norwegian De-
partment of Health and conducted by an independent
research institution, SINTEF Technology and Society.
One person was in charge of organizing the data collec-
tion from both patients and clinicians at each center.
The centers were selected to be demographically repre-
sentative for the country and the catchment areas of the
included clinics covered about 10% of the Norwegian
population in both urban and rural areas in different
regions of the country. The assessments were the same
across all sites and in both years. The two data-sets were
pooled into one for the current study.
Participants
All 6538 patients receiving treatment in the mental
health care centers were enrolled. Patients who returned
self-report questionnaires were included (N = 2246).
Patients were between 18 and 85 years old. Mean age
was 39.5 years (sd = 12.0).
Assessments
Patient rated assessments
Quality of life Patients completed the Manchester Short
Assessment of Quality of Life (MANSA) [18]. The
MANSA is designed to assess the quality of life of
patients with mental disorders and has satisfactory reli-
ability and validity for this patient group [18,19]. The
MANSA comprises four objective and 12 subjective
items and the subjective items were used in this study.
The items are designed to assess the satisfaction the
patients derive from the following domains: life as a
whole, job, financial situation, number and quality of
friendships, leisure activities, accommodation, personal
safety, people the patient lives with (or living alone), sex
life, relationship with family, physical health, and mental
health. The MANSA is rated on a 7-point Likert scale
(1 = couldn’t be worse, 7 = couldn’t be better). The score
used in this study is the mean of the 12 items. 344
patients did not complete the MANSA. Cronbach’s alpha
was 0.87 for the included sample.
Symptom severity Patients completed the Symptom
Checklist – 25 (SCL-25) in 2002, and the Symptom
Checklist – 10 (SCL-10) in 2005. Both are short versions
of the SCL-90-R, which has been extensively used in re-
search and clinical settings, and the Norwegian transla-
tions have satisfactory reliability and validity [20]. The
SCL-25 consists of 25 items, and the SCL-10 consists of
10 items, describing severity of psychiatric symptoms
rated on a 4-point scale (1 = not at all, 2 = a little severe,
3 = quite severe, 4 = very severe). All items on the SCL-
10 are present in the SCL-25 and only the SCL-10 items
were used in the current study. 101 patients did not
complete the SCL-10 and the Cronbach’s alpha was 0.89
for the included sample. A mean score of 1.85 or higher
indicates mental disturbance on the SCL-10 [20].
Benefit from treatment Patients evaluated the degree
of benefit they had received from treatment at the time
of the study. The patients rated four domains using a 5-
point Likert scale (1 = very little benefit, 2 = rather little,
3 = neither little nor much, 4 = quite much, 5 = very
much benefit). The four domains were: symptom reduc-
tion, symptom management skills, practical day-to-day
functioning, and ability to work. 154 patients did not
complete the treatment evaluation and Cronbach’s alpha
for the four domains was 0.79 for the included sample.
Sleep disturbance Three items measure sleep disturb-
ance on the SCL-90R. On the SCL-25 and SCL-10, these
three items have been reduced to one item measuring
severity of sleep disturbance the past 14 days on a 1 to 4
likert scale (How much have sleep problems disturbed
you the past 14 days: 1 = not at all, 2 = a little severe,
3 = quite severe, 4 = very severe disturbance). This item
was used to assess patient rated level of sleep disturb-
ance. The use of such a simple dimensional measure of
sleep quality is in accordance with the proposals for field
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trials made by the DSM-5 Sleep-Wake Disorders Work-
group and Advisors [21].
Clinician rated assessments
Disturbance severity The clinicians used the Health of
Nations Outcome Scales (HoNOS) to evaluate the
patients’ level of disturbance severity. The HoNOS is a
12-item clinician rated scale designed to measure the
health and social functioning of patients with mental
disorders. It has been widely used for patients in mental
health care settings, and a review of the studies on the
psychometric properties concluded that the HoNOS has
adequate reliability and validity [22] The HoNOS has
four subscales, behavior problems, cognitive impairment,
symptoms and social functioning, and all items are rated
on a 0 – 4 scale (0 = no problem, 1 = minor problem re-
quiring no action, 2 = mild problem but definitely
present, 3 = moderately severe problem, 4 = severe to
very severe problem) [23]. The sum score of the HoNOS
was used to assess the level of disturbance severity. Be-
cause the instructions on how to code item 8 (symp-
toms) where somewhat different in the two data-sets,
this item was omitted from the sum score in the main
analyses. The sum score of the HoNOS was 10.2 (SD =
4.9) for all 12 items on the HoNOS. Please see Table 1
for the sum score the HoNOS with item 8 omitted.
There were missing items on 442 patients on the
HoNOS.
Global assessment of functioning The clinicians used
a split version of the Global Assessment of Functioning
Scale. The Global Assessment of Functioning Scale is
described in Axis V of the Diagnostic and Statistical
Manual of Mental Disorders – IV (DSM-IV) [4]. The
split version is divided into one function score (GAF-F)
and one symptom score (GAF-S). This has been done
because of skepticism concerning the use of a single
scale to measure both level of social and occupational
function and severity of psychiatric symptoms [24]. The
split version is reliable and consistent across raters [25].
Functioning The GAF-F is a clinician rated 0–100 scale
measuring the social, occupational, and psychological
functioning of adults, e.g., how well or adaptively one is
meeting various problems in living. There were missing
data for 301 patients on the GAF-F.
Symptom severity The GAF-S was used to assess the
patients’ overall level of symptom severity. The GAF-S is
a clinician rated 0–100 scale measuring the level of
symptomatic distress [25]. There were missing data for
301 patients on the GAF-S.
Improvement from treatment Clinicians rated the level
of improvement from the beginning of treatment to
the point of data collection on three domains using a
7-point Likert scale (1 = much worse, 2 = a little worse,
3 = no change, 4 = a little better, 5 = a bit better, 6 = much
better, 7 = very much better). The three domains were:
psychiatric symptoms, practical day-to-day functioning,
and ability to work. Treatment improvement was not
evaluated for 188 patients and Cronbach’s alpha for the
three domains was 0.81 for the included sample.
Primary diagnoses
Patients were assigned one primary and up to two add-
itional ICD-10 [5] diagnoses according to ordinary clin-
ical practice. We used the primary diagnosis in this
study. Diagnoses were first grouped into the ten main
diagnostic chapters of the ICD-10 chapter 5: F0 Organic,
including symptomatic, mental disorders; F1 Mental and
behavioral disorders due to psychoactive substance use;
F2 Schizophrenia, schizotypal and delusional disorders;
F3 Mood disorders; F4 Neurotic, stress-related and soma-
toform disorders; F5 Behavioral syndromes associated
Table 1 Mean scores on the independent variables for the patients from eight public mental health care centres who
were included in the study
Mean (SD) n Response+ (%)
Patient rated variables
Manchester Short Assessment of Quality of Life 4.2 (0.9) 1902 84.7
Symptom Checklist – 10 2.4 (0.7) 2124 94.6
Benefit from Treatment 2.9 (1.1) 1657 91.5
Clinician rated variables
Health of Nations Outcome Scales sum++ 7.8 (4.5) 1804 80.3
Global Assessment of Functioning - Function 55.0 (10.6) 1945 86.6
Global Assessment of Functioning - Symptoms 54.6 (12.3) 1945 86.6
Benefit from Treatment 4.1 (1.0) 1721 95.0
Notes.
+ Of included patients.
++ Sum score omitting item 8.
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with physiological disturbances and physical factors;
F6 Disorders of adult personality and behavior; F7
Mental retardation; F8 Disorders of psychological devel-
opment; and F9 Behavioral and emotional disorders with
onset usually occurring in childhood and adolescence.
Because few patients had received any of the diagnosis of
F0 Organic, F1 Substance related, F5 Behavioral Syn-
dromes, F7 Retardation, F8 Developmental, and F9
Childhood disorders, these patients were grouped into
one group entitled Other Disorders in the analyses (N =
175). 291 patients had not received an ICD-10 diagnosis
of mental or behavioral disorder at the time of data col-
lection. No patients had received a diagnosis of insomnia
or any other sleep related diagnoses as a primary or
comorbid diagnosis.
Treatment duration
The number of months the patients had been in treatment
at the time of the study was 14.5 months (sd = 28.7),
whereas the median duration of treatment was 7 months.
Types of care
Patients were either receiving treatment as in-patients or
out patients.
Statistical analyses
The dependent variables in the statistical analyses were
quality of life, patient rated symptom severity, patient
rated benefit from treatment, disorder severity, level of
functioning, clinician rated level of symptom severity
and clinician rated benefit from treatment.
To examine differences in level of sleep disturbance in
the different primary diagnostic groups we performed a
one-way analysis of variance (ANOVA). To test if there
were differences in levels of sleep disturbance between
type of care, and men and women we performed two in-
dependent t-tests.
Six of the seven dependent variables were normally
distributed and used in six hierarchical multiple regres-
sion analyses to test if sleep disturbance was related to
the dependent variables independently of age and gen-
der, time in treatment, type of care and primary diagno-
ses. We entered age and gender in step 1, time in
treatment in step 2, type of care in step 3, primary diag-
nostic groups in step 4, sleep disturbance in step 5, and
the interactions between sleep disturbance and the pri-
mary diagnostic groups in step 6. Because the variable
“Clinician rated improvement from treatment” was not
normally distributed, and could not be normalized, we
dichotomized this variable and performed logistic re-
gression analysis to test if sleep disturbance was related
to good or poor clinician rated improvement from treat-
ment. Patients with worsening or no improvement from
treatment were classified as having “poor outcome” and
patients with various degrees of improvement were clas-
sified as having “good outcome”. The logistic regression
analysis was performed with the same hierarchical struc-
ture as the linear regression analyses.
Because of the number of statistical analyses, we Bon-
ferroni corrected the level of significance to p < 0.007.
Missing data was handled using listwise deletion. Mean
score for the SCL was calculated omitting the sleep item.
The statistical analyses were performed using PASW
version 18 for Mac Os X.
Ethics
The study was approved by the Regional Ethical Com-
mittee for Research in Health and by the Norwegian
Data Inspectorate. The Directorate of Health and Social
Affairs gave consent for the use of information from the
health services.
Results
Descriptive and preliminary analyses
Diagnostic distribution, type of care and gender is
reported in Table 2 along with the mean scores and
standard deviations on sleep disturbance for each group.
Mean scores, standard deviations, and response rates
on the dependent variables are shown in Table 1.
Patients with an ICD-10 diagnosis of Schizophrenia
(chapter F20) reported significantly lower levels of sleep dis-
turbance than other patients (F (4, 1942) = 11.9, p < 0.0001).
Levels of sleep disturbance were not different between
patients in different types of care (t (2233) = 0.46, p = 0.64)
or between men and women (t (2195) = 1.51, p = 0.13).
Results from steps 1 – 4 of the regression analyses
The complete results from the seven regression analyses
are shown in the Additional files. Please see Additional
file 1: Table S1, Additional file 2: Table S2, Additional
file 3: Table S3, Additional file 4: Table S4, Additional file 5:
Table S5, Additional file 6: Table S6, Additional file 7:
Table S7.Below is a summary of the significant results
from steps 1 to 4 of the regression analyses.
Step 1. Older age was associated with higher quality of
life (β = 0.10, t = 3.95, p < 0.0001).
Step 2. Longer duration of treatment was associated
with higher degree of patient rated (β = 0.09, t = 3.60,
p = 0.0003) and clinician rated (B = −0.02, wald = 36.9,
p < 0.0001) improvement from treatment.
Step 3. Being an in-patient was associated with poorer
quality of life (β = −0.10, t = 3.81, p = 0.0002), higher
patient rated symptom severity (β = 0.09, t = 3.88,
p = 0.0001), higher disorder severity (β = 0.17, t = 6.79,
p < 0.0001), lower level of functioning (β = − 0.23, t =
9.97, p < 0.0001), higher clinician rated symptom severity
(β = − 0.24, t = 10.3, p < 0.0001), and lower clinician
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rated benefit from treatment (B = −0.38, wald = 8.76,
p = 0.003).
Step 4. Patients assigned a diagnosis of Schizophrenia
had lower patient rated symptom severity (β = − 0.16,
t = 2.93, p = 0.003), lower levels of functioning
(β = − 0.24, t = 4.05, p = 0.0001), and higher levels of
clinician rated symptom severity (β = −0.32, t = 5.66,
p < 0.0001).
Hypothesis testing
Level of sleep disturbance, entered in the fifth step of
the regression analyses, was significantly and uniquely
associated with all the seven dependent variables. See
Table 3 for a summary of these results. The interactions
between sleep disturbance and specific diagnoses,
entered in step 6, were not significantly associated with
any of the dependent variables.
Discussion
Main findings
We found that higher levels of sleep disturbance were
associated with significantly lower quality of life, higher
distress and functional impairment, and less benefit from
treatment for patients in mental health care, independently
of their primary diagnosis. To our knowledge, it is the first
time this has been shown in a large sample of patients
representative of public mental health care clinics. These
results might encourage clinicians to assess and provide
specific treatment for sleep disturbance to patients with
mental disorders as this might improve treatment results.
The DSM definition of a mental disorder is “a behavior
or psychological syndrome that is associated with
present distress or disability” [4]. Our results are in line
with this definition, and with the recommendation from
the NIH [16], and the suggested change in the DSM-5
[17], that sleep disturbance in patients with mental dis-
orders may be regarded as a standalone therapeutic en-
tity comorbid to the primary mental disorder.
Interpretation in relation to previous research
The present study demonstrates associations between
sleep disturbance and patient rated quality of life and
clinician rated disorder severity and level of functioning.
Quality of life has been defined as “a concept encom-
passing a broad range of physical and psychological
characteristics and limitations which describe an
Table 2 Descriptive and clinical data for patients from
eight public mental health care centres included in the
study
n (%) Mean Level of
Sleep Disturbance
(sd)
Primary diagnoses
Schizophrenia 218 (9.7) 1.89 (0.98)
Mood disorders 799 (35.6) 2.39 (1.02)
Anxiety disorders 538 (24.0) 2.39 (1.02)
Personality disorders 225 (10.0) 2.39 (1.06)
Other disorders 175 (7.8) 2.39 (1.06)
No diagnosis 291 (13.0) 2.32 (1.06)
Type of care
Out-patients 1754 (78.1) 2.34 (1.04)
In-patients 492 (21.9) 2.31 (1.01)
Gender
Female 1127 (51.0) 2.36 (1.04)
Male 1081 (49.0) 2.29 (1.03)
Table 3 Summary of six linear hierarchical regression analyses and one logistic hierarchical regression analysis
assessing the unique associations between sleep disturbance and the dependent variables adjusted for age, gender,
time in treatment, type of care, and diagnoses for patients from eight public mental health care centres
Dependent variables Adj. R2 ΔR2 B S.E. B β t
Patient rated variables
Quality of Life 0.12 0.08 −0.26 0.02 −0.29** 12.0
Symptom severity 0.20 0.17 0.29 0.02 0.42** 19.2
Benefit from treatment 0.02 0.01 −0.08 0.03 −0.08* 3.3
Clinician rated variables
Disorder severity 0.11 0.05 0.97 0.10 0.22** 9.3
Level of functioning 0.13 0.02 −1.82 0.27 −0.15** 6.7
Symptom severity 0.17 0.02 −1.59 0.23 −0.16** 6.9
B S.E. B Wald OR
Benefit from treatment+ 0.33 0.05 40.7** 1.39
Notes. * p = 0.001, ** p < 0.0001. +Clinician rated benefit from treatment was tested using logistic regression analysis. Only sleep disturbance entered in the fifth
step is shown in the table, except Adj. R2 which is the explained variance of all steps in the regression analyses. ΔR2 is the explained variance of sleep disturbance
entered in the fifth step of the regression analyses.
Quality of Life = Mean score on the Manchester Assessment of Quality of Life. Patient rated Symptom Severity = The mean score of the Symptom Checklist
(omitting the sleep item). Disorder Severity = The Sum Score of the Health of Nations Outcome Scales. Level of Functioning = The Global Assessment of
Functioning Scale (split version) Function Subscale. Clinician rated Symptom Severity = The Global Assessment of Functioning Scale (split version) Symptom
Subscale.
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individual’s ability to function and to derive satisfaction
from doing so” [26]. The MANSA measures the patients’
satisfaction with social, professional, physical and emo-
tional factors. The HoNOS measures mental and social
functioning, whereas the GAF measures the general level
of functioning. As such, our combined results, encom-
passes these broad features of quality of life laid out in
the above definition. In 2005 the NIH recommended
that future studies should focus on the association be-
tween quality of life and sleep disturbance [16], and
emerging reports from the last years describe individuals
with sleep disturbance to have poor quality of life
[26,27] independently of somatic complaints [27,28] and
also when the sleep disturbance is comorbid to depres-
sion [29]. Thus our study extends the current body of
research by showing that sleep disturbance is associated
with poor subjective quality of life and functioning in all
patient groups in mental health care.
An important finding from the current study was that
higher levels of sleep disturbance were strongly asso-
ciated with higher levels of psychiatric symptom severity
as measured by both clinicians and patients. This is
similar to previous findings where patients with primary
insomnia report high levels of emotional distress [30]
and more negative affect [31]. Depressed patients with
insomnia also report higher levels of symptom severity
than depressed patients without insomnia [29,32], and
the current study extends these findings to patients with
other mental disorders. In sum, it is becoming more
likely that sleep disturbance has a unique contribution
to patients’ level of psychiatric symptom severity, their
daily functioning and their quality of life that cannot be
accounted for by the presence of other mental disorders.
The results from the present study also raise the ques-
tion if sleep disturbance affects treatment outcome. We
found that higher levels of sleep disturbance were asso-
ciated with deriving less benefit from treatment as mea-
sured by both patients and clinicians. These results are
in line with previous research on the impact of sleep dis-
turbance on the treatment of depression. Untreated,
sleep disturbance in depressed patients predicts poorer
response to psychotherapy [33] and is the most common
residual symptom after successful treatment of depres-
sion [11,12]. On the other hand, providing specific treat-
ment for insomnia for patients with major depression
who are receiving anti-depressant medication can en-
hance the effect of the medication [14,34] and improve
quality of life [35]. One study even found that only pro-
viding cognitive behavior therapy for insomnia (CBT-I)
to patients with mild depression normalized depression
scores in 87% of the patients [15]. Interestingly, a recent
pilot trial of CBT-I in 15 patients with persistent perse-
cutory delusions and comorbid insomnia gave very
promising results. Treatment with CBT-I did not only
lead to large improvements in the insomnia of these
patients but were also associated with large improve-
ments in persecutory delusions [36]. There is less know-
ledge about the clinical impact of sleep in the treatment
of anxiety disorders. However, one study found that
sleep does not improve after successful treatment of
panic disorder [37]. Providing CBT-I for patients with
Post Traumatic Stress Disorder (PTSD) can also im-
prove both sleep quality and other PTSD symptoms in-
cluding nightmare frequency [38]. Thus, from the body
of research that has been conducted so far, it seems that
treating sleep disturbance may enhance treatment out-
come, whereas no treatment for sleep disturbance could
result in poorer outcome. From the findings in the
present study it would be interesting for future research
to explore if providing specific treatment of sleep dis-
turbance in any mental disorder can have similar posi-
tive results.
Indeed, an interesting finding from the current study
was that sleep disturbance was equally common in all
diagnostic groups with the exception of schizophrenia,
where there was less. This is in line with a recent review
highlighting sleep disturbance as a potential transdiag-
nostic mechanism across mental disorders [39]. From a
neurobiological point of view, Harvey et al. proposes
that there is a bidirectional relationship between sleep
disturbance and emotion regulation that may account
for how sleep disturbance and emotional distress are
linked in mental disorders [39]. Our finding is also simi-
lar to the conclusions of a meta-analysis of polysomno-
graphically measured sleep in psychiatric patients where
no differences between diagnostic categories could be
found [40]. The low frequency of self-reported sleep dis-
turbance among patients suffering from schizophrenia
both in the present study and an earlier study [41] might
both be explained by selection of patients, problems with
insight, and characteristics of the illness.
Limitations
There are limitations to the study that should be noted.
First, the treatment results were rated retrospectively
using rating scales that had not previously been vali-
dated. Social desirability factors, expectancy effects, and
the patients’ feedback might have biased the clinician
rated improvement scores and it is worth noticing that,
on average, the clinicians reported more favorable out-
comes than the patients did. This might explain why the
clinicians’ rated outcomes were not normally distributed.
Second, there may be selection biases, as about two-
thirds of the original sample of patients did not agree to
have their self-report linked to the clinician- report. This
could be an artifact of the procedures. The patients had
to specifically indicate that they wanted to have their
scores linked to their clinicians’ ratings, rather than
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having to indicate if they did not want to have their
scores linked. This difference could have had a large im-
pact on patient participation [42]. However, our sample
of patients seems representative of patients in public
mental health care settings compared to findings from
similar samples in other countries using the same mea-
sures [18,20,23,43-45]. Third, in the current study, the
limited explained variance on some measures may be
due to the study design. The study was commissioned
by the Norwegian department of health to evaluate the
state of the National mental health care system and was
not designed specifically to evaluate the effects of co-
occurring sleep disturbance in patients with mental dis-
orders. Fourth, the cross-sectional design of the study
does not allow for conclusions about causality and we
cannot elucidate the exact relationship between sleep
disturbance and symptom severity. Moreover, the study
is not able to identify the potential underlying mechan-
isms that might link sleep disturbance to various mental
disorders [39]. Fifth, a single item measuring sleep dis-
turbance was used. This means that we cannot discern
the relative impact of sleep onset or sleep maintenance
problems or if the patients experienced other kinds of
sleep disturbance. Still, it is remarkable that a single item
measuring sleep disturbance had a significant effect on
all included dependent variables. Indeed, that a single
item can be used to get significant results is in line with
previous research and may be useful for clinicians [46].
The work-group for sleep disorders in the DSM-5 revi-
sion has recently called for data from clinical settings
with simple dimensional measures of sleep quality [21].
To compensate for these limitations, future studies
should have a prospective study design where measure-
ments are done before, during, and after treatment using
validated outcome measures and scales adjusting for so-
cial desirability.
Conclusions
In mental health care settings, sleep disturbance has a
unique association with quality of life, symptom severity,
disorder severity, level of functioning, and benefit from
treatment over and above the effects of age, gender, time
in treatment, type of care, and primary diagnoses. Thus,
sleep disturbance ought to be considered a stand-alone
therapeutic entity rather than an epiphenomenon of
existing diagnoses for patients receiving treatment in
mental health care.
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